Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Immunologic Research
Erschienen in: Immunologic Research 1/2017

19.07.2016 | Environment and Autoimmunity

Autoimmune reaction after anti-tetanus vaccination—description of four cases and review of the literature

verfasst von: N. Ruhrman-Shahar, J. Torres-Ruiz, P. Rotman-Pikielny, Y. Levy

Erschienen in: Immunologic Research | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Autoimmune reaction after vaccination is sporadically reported in the medical literature. Vaccinations are generally safe and have an important role in eradicating endemic diseases worldwide. Nevertheless, the question arises as to whether there is a possibility of post-vaccination autoimmune phenomena. The anti-tetanus vaccine is being used since 1924, and it is part of the recommended immunization schedules for children. There are few reports of autoimmune diseases, such as rheumatoid arthritis and anti-phospholipid syndrome after anti-tetanus vaccination. Herein, we describe four cases, of which we believe, show a clear temporal relation between anti-tetanus vaccination and the appearance of dermatomyositis, systemic lupus erythematosus, type 1 diabetes mellitus and anti-phospholipid syndrome. We also suggest some of the pathogenic mechanisms that promote a pathogenic autoimmune response.
Literatur
1.
Shoenfeld Y, Agmon-Levin N, Tomljenovic L. Vaccines and autoimmunity. Vancouver: Wiley-Blackwell; 2015.CrossRef
2.
Hua C, Morel J, Ardouin E, Ricard E, Foret J, Mathieu S, et al. Reasons for non-vaccination in French rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford). 2015;54(4):748–50.CrossRef
3.
Salami S, D’Amelio R. Could autoimmunity be induced by vaccination? Int Rev Immunol. 2010;29(3):247–69.CrossRef
4.
Benoist C, Mathis D. Autoimmunity provoked by infections; how good is the case for T cell epitope mimicry? Nat Immunol. 2001;2(9):797–801.CrossRefPubMed
5.
Wraith DC. Vaccination an autoimmune diseases: what is the evidence? Lancet. 2003;362(9396):1659–66.CrossRefPubMed
6.
Fujinami RS, von Herrath MG, Christen U, Whitton JL. Molecular mimicry, by-stander activation or viral persistence: infections and autoimmune disease. Clin Microbiol Rev. 2006;19(1):80–94.CrossRefPubMedPubMedCentral
7.
Shoenfeld Y, Agmon-Levin N. ASIA autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011;36(1):4–8.CrossRefPubMed
8.
Perricone C, Colafrancesco S, Mazor RD, Soriano A, Agmon-Levin N, Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: unveiling the pathogenic, clinical and diagnostic aspects. J Autoimmun. 2013;47:1–16.CrossRefPubMed
9.
Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 2004;82(5):488–96.CrossRefPubMed
10.
Miller E, Waight P, Farrington CP, Andrews N, Stowe J, Taylor B. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child. 2001;84(3):227–9.CrossRefPubMedPubMedCentral
11.
Beeler J, Varricchio F, Wise R. Thrombocytopenia after immunization with measles vaccines: review of the vaccine adverse events reporting system (1990–1994). Pediatr Infect Dis J. 1996;15(1):88–90.CrossRefPubMed
12.
Nieminen U, Peltola H, Syrjälä MT, Mäkipernaa A, Kekomäki R. Acute thrombocytopenic purpura following measles, mumps and rubella vaccination. Acta Paediatr. 1993;82:267–70.CrossRefPubMed
13.
Jonville-Béra AP, Autret E, Galy-Eyraud C, Hessel L. Thrombocytopenic purpura after measles, mumps and rubella vaccination: a retrospective survey by the French regional pharmacovigilance centres and pasteur-mérieux sérums et vaccins. Pediatr Infect Dis J. 1996;15(1):44–8.CrossRefPubMed
14.
15.
Marks JS, Halpin TJ. Guillain–Barré syndrome in recipients of A/New Jersey influenza vaccine. JAMA. 1980;243(24):2490–4.CrossRefPubMed
16.
Langmuir AD. Guillain–Barré syndrome: the swine influenza virus vaccine incident in the United States of America, 1976–77: preliminary communication. J R Soc Med. 1979;72(9):660–9.CrossRefPubMedPubMedCentral
17.
Eisen DP, McBryde ES. Avoiding Guillain–Barré syndrome following swine origin pandemic H1N1 2009 influenza vaccination. J Infect Dis. 2009;200(10):1627–8.CrossRefPubMed
18.
Lasky T, Terracciano GJ, Magder L, Koski CL, Ballesteros M, Mash D, et al. The Guillain–Barré syndrome and the 1992–1993 and 1993–1994 influenza vaccines. N Engl J Med. 1998;339:1797–802.CrossRefPubMed
19.
Juurlink DN, Stukel TA, Kwong J, Kopp A, McGeer A, Upshur RE, et al. Guillain–Barré syndrome after influenza vaccination in adults: a population-based study. Arch Intern Med. 2006;166(20):2217–21.CrossRefPubMed
20.
21.
Aksu K, Keser G, Doganavsargil E. Reactive arthritis following tetanus and rabies vaccinations. Rheumatol Int. 2006;27(2):209–10.CrossRefPubMed
22.
Agmon-Levin N, Zafrir Y, Paz Z. Ten cases of systemic lupus erythematosus related to hepatitis B vaccine. Lupus. 2009;18(13):1192–7.CrossRefPubMed
23.
Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from advisory committee on immunization practice. MMWR Morb Mortal Wkly Rep. 2011;60(1):13–5.
24.
Meir A, Rotman-Pikielny P, Levy Y. Antiphospholipid syndrome following a diphtheria-tetanus vaccination: coincidence vs. causality. Isr Med Assoc J. 2010;12(10):638–9.
25.
Zafrir Y, Agmon-Levin N, Paz Z, Shilton T, Shoenfeld Y. Autoimmunity following Hepatitis B vaccine as part of the spectrum of ‘Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants’ (ASIA): analysis of 93 cases. Lupus. 2012;21(2):146–52.CrossRefPubMed
26.
Cerpa-Cruz S, Paredes-Casillas P, Landeros Navarro E, Bernard-Medina AG, Martinez-Bonilla G, Gutierrez-Urena S. Adverse events following immunization with vaccines containing adjuvants. Immunol Res. 2013;56(2–3):299–303.CrossRefPubMed
27.
Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Adjuvants and autoimmunity. Lupus. 2009;18:1217–25.CrossRefPubMed
28.
Guimaraes LE, Baker B, Perricone C, Shoenfeld Y. Vaccines, adjuvants and autoimmunity. Pharmacol Res. 2015;100:190–209.CrossRefPubMed
29.
Ghimire TR, Benson RA, Garside P, Brewer JM. Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro. Immunol Lett. 2012;147(1–2):55–62.CrossRefPubMedPubMedCentral
30.
Kool M, Fierens K, Lambrecht BN. Alum adjuvant: some of the tricks of the oldest adjuvant. J Med Microbiol. 2012;61(Pt 7):927–34.CrossRefPubMed
31.
Cruz-Tapias P, Agmon-Levin N, Israeli E, Anaya JM, Shoenfeld Y. Autoimmune (Auto-inflammatory) syndrome induced by adjuvants (ASIA): animal models as a proof of concept. Curr Med Chem. 2013;20:4030–6.CrossRefPubMed
32.
Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Macrophagic myofaciitis a vaccine (alum) autoimmune-related disease. Clin Rev Allergy Immunol. 2011;41(2):163–8.CrossRefPubMed
33.
Agmon-Levin N, Arango MT, Kivity S, Katzav A, Gilburd B, Blank M, et al. Immunization with hepatitis B vaccine accelerates SLE-like disease in a murine model. J Autoimmun. 2014;54:21–32.CrossRefPubMed
34.
Franchi L, Nunez G. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur J Immunol. 2008;38(8):2085–9.CrossRefPubMedPubMedCentral
35.
Ulanova M, Tarkowski A, Hahn-Zoric M, Hanson LA. The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immun. 2001;69(2):1151–9.CrossRefPubMedPubMedCentral
36.
Ligi D, Santi M, Croce L, Mannello F. Aluminum induces inflammatory and proteolytic alterations in human monocytic cell line. J Inorg Biochem. 2015;152:190–8.CrossRefPubMed
37.
Dalakas MC. Inflammatory muscle diseases: a critical review on pathogenesis and therapies. Curr Opin Pharmacol. 2010;10(3):346–52.CrossRefPubMed
38.
Venalis P, Lundberg IE. Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy. Rheumatology (Oxford). 2014;53(3):397–405.CrossRef
39.
O’Hanlon TP, Carrick DM, Arnett FC, Reveille JD, Carrington M, Gao X, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies. Medicine. 2005;84(6):338–49.CrossRefPubMed
40.
41.
Gherardi RK, Coquet M, Cherin P, Belec L, Moretto P, Dreyfus PA, et al. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain. 2001;124:1821–31.CrossRefPubMed
42.
Sugiura T, Harigai M, Kawaguchi Y, Takagi K, Fukasawa C, Oshako-Higami S, et al. Increased IL-15 production of muscle cells in polymyositis and dermatomyositis. Int Immunol. 2002;14(8):917–24.CrossRefPubMed
43.
Lepidi H, Frances V, Figarella-Branger D, Bartoli C, Machado-Baeta A, Pellissier JF. Local expression of cytokines in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol. 1998;24:73–9.CrossRefPubMed
44.
45.
Grammatikos AP, Tsokos GC. Immunodeficiency and autoimmunity: lessons from systemic lupus erythematosus. Trends Mol Med. 2012;18(2):101–8.CrossRefPubMed
46.
Tucci M, Quatraro C, Lombardi L, Pellegrino C, Dammacco F, Silvestris F. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis Rheum. 2008;58(1):251–62.CrossRefPubMed
47.
48.
Doria A, Sarzi-Puttini P, Shoenfeld Y. Infections, rheumatism and autoimmunity: the conflicting relationship between humans and their environment. Autoimmun Rev. 2008;8(1):1–4.CrossRefPubMed
49.
Fourneau JM, Bach JM, van Endert PM, Bach JF. The elusive case for a role of mimicry in autoimmune diseases. Mol Immunol. 2004;40:1095–102.CrossRefPubMed
50.
Sfriso P, Ghirardello A, Botsios C, Tonon M, Zen M, Bassi N, et al. Infections and autoimmunity: the multifaceted relationship. J Leukoc Biol. 2010;87:385–95.CrossRefPubMed
51.
Aslanidis S, Pyrpasopoulou A, Kontotasios K, Doumas S, Zamboulis C. Parvovirus B19 infection and systemic lupus erythematosus: activation of an aberrant pathway? Eur J Intern Med. 2008;19(5):314–8.CrossRefPubMed
52.
Boele LC, Bajramovic JJ, De Vries AM, Voskamp-Visser IA, Kaman WE, Van Der Kleij D. Activation of toll-like receptors and dendritic cells by a broad range of bacterial molecules. Cell Immunol. 2009;255(1–2):17–25.CrossRefPubMed
53.
Lovgren T, Eloranta ML, Bave U, Alm GV, Ronnblom L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 2004;50(6):1861–72.CrossRefPubMed
54.
Gottenberg JE, Chiocchia G. Dendritic cells and interferon-mediated autoimmunity. Biochimie. 2007;89:856–71.CrossRefPubMed
55.
Richardson SJ, Willcox A, Bone AJ, Morgan NG, Foulis AK. Immunopathology of the human pancreas in type-I diabetes. Semin Immunopathol. 2011;33(1):9–21.CrossRefPubMed
56.
Hviid A, Stellfeld M, Wohlfarhrt J, Melbye M. Childhood vaccination and type 1 diabetes. N Engl J Med. 2004;350(14):1398–404.CrossRefPubMed
57.
Coppieters KT, Roep BO, Von Herrath MG. Beta cells under attack: toward a better understanding of type 1 diabetes immunopathology. Semin Immunopathol. 2011;33(1):1–7.CrossRefPubMed
58.
Reynaud Q, Lega JC, Mismetti P, Chapelle C, Wahl D, Cathénebras P, et al. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev. 2014;13(6):595–608.CrossRefPubMed
59.
Blank M, Krause I, Fridkin M, Keller N, Kopolovic J, Goldberg I, et al. Bacterial induction of autoantibodies to β2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Investig. 2002;109(6):797–804.CrossRefPubMedPubMedCentral
60.
Inic-Kanada A, Stojanovic M, Zivkovic I, Kosec D, Micic M, Petrusic V, et al. Murine monoclonal antibody 26 raised against tetanus toxoid cross-reacts with beta2-glycoprotein I: its characteristics and role in molecular mimicry. Am J Reprod Immunol. 2009;61(1):39–51.CrossRefPubMed
61.
Zivkovic I, Stojanovic M, Petrusic V, Inic-Kanada A, Dimitrijevic L. Induction of APS after TTd hyper-immunization has a different outcome in BALB/c and C57BL/6 mice. Am J Reprod Immunol. 2011;65(5):492–502.CrossRefPubMed
62.
Petrusic V, Zivkovic I, Muhandes L, Dimitrijevic R, Stojanovic M, Dimitrijevic L. Infection-induced autoantibodies and pregnancy related pathology: an animal model. Reprod Fertil Dev. 2014;26(4):578–86.CrossRefPubMed
63.
Petrusic V, Todorovic N, Zivkovic I, Dimitrijević R, Muhandes L, Rajnpreht I, et al. Autoantibody response and pregnancy-related pathology induced by combined LPS and tetanus toxoid hyperimmunization in BALB/c and C57BL/6 mice. Autoimmunity. 2015;48(2):87–99.CrossRefPubMed
Metadaten
Titel
Autoimmune reaction after anti-tetanus vaccination—description of four cases and review of the literature
verfasst von
N. Ruhrman-Shahar
J. Torres-Ruiz
P. Rotman-Pikielny
Y. Levy
Publikationsdatum
19.07.2016
Verlag
Springer US
Erschienen in
Immunologic Research / Ausgabe 1/2017
Print ISSN: 0257-277X
Elektronische ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-016-8822-x

Weitere Artikel der Ausgabe 1/2017

Immunologic Research 1/2017 Zur Ausgabe

Environment and Autoimmunity

Involvement of chronic epipharyngitis in autoimmune (auto-inflammatory) syndrome induced by adjuvants (ASIA)

Therapeutic Aspects in Autoimmunity

Rituximab therapy for IgA-vasculitis with nephritis: a case series and review of the literature

Environment and Autoimmunity

Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literature

Therapeutic Aspects in Autoimmunity

Hepatitis B carrier state among SLE patients: case–control study

Environment and Autoimmunity

Adjuvants- and vaccines-induced autoimmunity: animal models

Mechanism in Autoimmunity

Tolerance, loss of tolerance and regaining tolerance to self by immune-mediated events

Neu im Fachgebiet HNO

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

HNO-Op. auch mit über 90?

16.04.2024 HNO-Chirurgie Nachrichten

Mit Blick auf das Risiko für Komplikationen nach elektiven Eingriffen im HNO-Bereich scheint das Alter der Patienten kein ausschlaggebender Faktor zu sein. Entscheidend ist offenbar, wie fit die Betroffenen tatsächlich sind.

Intrakapsuläre Tonsillektomie gewinnt an Boden

16.04.2024 Tonsillektomie Nachrichten

Gegenüber der vollständigen Entfernung der Gaumenmandeln hat die intrakapsuläre Tonsillektomie einige Vorteile, wie HNO-Fachleute aus den USA hervorheben. Sie haben die aktuelle Literatur zu dem Verfahren gesichtet.

Bilateraler Hörsturz hat eine schlechte Prognose

15.04.2024 Hörsturz Nachrichten

Die Mehrzahl der Menschen mit Hörsturz ist einseitig betroffen, doch auch ein beidseitiger Hörsturz ist möglich. Wie häufig solche Fälle sind und wie sich ihr Verlauf darstellt, hat eine HNO-Expertenrunde aus den USA untersucht.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise